Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial assessing ublituximab + umbralisib with or without bendamustine, and umbralisib alone, in previously treated non-Hodgkin lymphoma; study termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Ublituximab (ublituximab)
• umbralisib

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 2, Phase 3 | Status: TERMINATED